Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
LUM-201 Long-term Extension Study in Children With Growth Hormone Deficiency
NCT07129759Phase 3Not yet recruiting
- Sponsor
- Lumos Pharma, Inc.
- Start
- Feb 2027
- Primary completion
- Feb 2030
- Modality
- Small Molecules
01
Overview
A Phase 3 trial of ibutamoren in growth hormone deficiency (GHD), sponsored by Lumos Pharma, Inc.. Planned start Feb 2027; status: not yet recruiting.
02
Drugs
ibutamoren
03
Conditions
growth hormone deficiency (GHD)
Beyond the preview
Go deeper on NCT07129759.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT07129759.